Loading
Loading
Source Filing
Executive Record
Reported Pay
Compensation pending.
Findings
Reviewing FY2025 executive compensation against shareholder return and the latest filing-backed pay disclosures.
Spread between reported pay and stock performance is pending computation.
Evidence is sourced from the latest executive compensation filing and return series for AMPH.
Team view
5 executives
President Chief Scientific Officer
Total PayFY2025
$8.3M
Chief Operating Officer Chief
Total PayFY2025
$4.0M
Executive Vice President of Finance Treasurer, President of International Medication Systems, Limited, and Director
Total PayFY2025
$3.2M
President of Amphastar Nanjing Pharmaceuticals Co., Ltd
Total PayFY2025
$2.5M
Sales and Marketing Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
Total PayFY2025
$2.0M
Ask a question about this filing
01FY2025 total compensation breakdown
Activity timeline · FY2025
Recent events from filings
Apr 13, 2026
Jack Y. Zhang Equity award
Apr 13, 2026
William J. Peters Equity award
Apr 13, 2026
Mary Ziping Luo Equity award
Apr 13, 2026
Rong Zhou Equity award
Apr 13, 2026
Jacob Liawatidewi Equity award
A pay-performance summary will appear here once the verdict loads above.
02Pay changes vs. stock performance
1 year of data
Peer context
Dashed line marks the small-cap median compensation benchmark for companies around $855.2M market cap, based on 230 peers in this size band.
03Recent insider trades by officers and directors
~24 trades
04Showing FY2025 data (latest available)
FY2026does not include director compensation in our current dataset, so we're showing the latest board table we found.
We're loading the latest director compensation and board makeup.
05Take action on executive compensation
Shareholder activism tools
Start or join campaigns to engage with AMPH's board on executive compensation, governance, and shareholder proposals.
Activism Beta — Sign in to start or join campaigns
06For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $0.95M | $0.69M | $3.30M | $3.30M | $0.06M | $8.31M | |
| 2025 | $0.78M | $0.42M | $1.39M | $1.39M | $0.06M | $4.03M | |
| 2025 | $0.65M | $0.44M | $1.04M | $1.04M | $0.06M | $3.24M | |
| 2025 | $0.72M | $0.38M | $0.70M | $0.70M | $0.04M | $2.54M | |
| 2025 | $0.50M | $0.31M | $0.59M | $0.59M | $0.04M | $2.04M | |
| 2024 | $0.92M | $0.76M | $3.00M | $3.00M | $0.05M | $7.73M | |
| 2024 | $0.75M | $0.48M | $1.27M | $1.27M | $0.04M | $3.80M | |
| 2024 | $0.63M | $0.41M | $0.91M | $0.91M | $0.06M | $2.91M | |
| 2024 | $0.56M | $0.35M | $0.58M | $0.58M | $0.04M | $2.13M | |
| 2024 | $0.48M | $0.30M | $0.50M | $0.50M | $0.04M | $1.82M | |
| 2023 | $0.90M | $1.05M | $2.86M | $2.86M | $0.06M | $7.72M | |
| 2023 | $0.73M | $0.59M | $1.20M | $1.21M | $0.04M | $3.77M | |
| 2023 | $0.61M | $0.54M | $0.84M | $0.84M | $0.06M | $2.89M | |
| 2023 | $0.54M | $0.38M | $0.53M | $0.53M | $0.04M | $2.03M | |
| 2023 | $0.50M | $0.34M | $0.45M | $0.45M | $0.04M | $1.78M | |
| 2022 | $1.11M | $0.96M | $2.67M | $2.67M | $0.06M | $7.48M | |
| 2022 | $0.91M | $0.57M | $1.13M | $1.13M | $0.06M | $3.78M | |
| 2022 | $0.58M | $0.49M | $0.76M | $0.76M | $0.05M | $2.65M | |
| 2022 | $0.46M | $0.33M | $0.47M | $0.47M | $0.04M | $1.78M | |
| 2022 | $0.44M | $0.31M | $0.40M | $0.40M | $0.04M | $1.59M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.